Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab.
Bennett
Jeffrey L
JL
Thomas
Scott
S
Olson
Jeffrey L
JL
Mandava
Naresh
N
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002533:Cerebral Angiography; D005260:Female; D006801:Humans; D018917:Optic Neuropathy, Ischemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010211:Papilledema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D012161:Retinal Artery / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism; D015354:Vision, Low / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D014794:Visual Fields / Q000187:drug effects; D014822:Vitreous Body / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab